Skip to content
Review Open access

The Bidirectional Association Between MASLD and Male Hypogonadism: An Updated Meta-Analysis.

Jul 2026 · Andrology · 0 citations · 41 references
Medicine

TL;DR

A systematic review and meta-analysis supports a clinically relevant association between testosterone deficiency and MASLD, although evidence for the bidirectional nature of this relationship remains asymmetric but supports a clinically relevant endocrine-hepatic axis.

Abstract

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) and male hypogonadism are increasingly prevalent, metabolically interrelated conditions. Testosterone (T) deficiency has been implicated in hepatic lipid dysregulation, insulin resistance, and visceral adiposity, whereas MASLD may impair the hypothalamic-pituitary-gonadal axis. We conducted a systematic review and meta-analysis to evaluate the bidirectional association between circulating T levels and MASLD in adult men.

Methods

Following PRISMA guidelines, a literature search was performed from inception to July 31, 2025. Twenty-eight studies met the inclusion criteria (9 comparing hypogonadal vs. eugonadal men; 19 comparing MASLD vs. non-MASLD men). Random-effects models were used to pool effect sizes for dichotomous and continuous outcomes. Meta-regression analyses assessed the influence of age, anthropometric features, glycemic markers, liver enzymes, and hormonal parameters.

Results

Hypogonadal men showed a significantly higher prevalence of MASLD than eugonadal men (p = 0.001) and exhibited higher fatty liver index scores (p < 0.001). Total T concentrations were significantly lower in men with MASLD than in controls (p = 0.014). Meta-regression analyses did not identify significant effects of study-level differences in age, body mass index, or biochemical variables on the observed associations. Sex hormone-binding globulin levels were also significantly reduced in MASLD (p < 0.001), with age emerging as the only significant modifier. No significant differences were observed for luteinizing hormone, estradiol, or fibrosis-4 index. Across studies evaluating MASLD severity, moderate-to-severe disease was associated with lower T levels, particularly in analyses based on imaging.

Conclusions

This meta-analysis supports a clinically relevant association between testosterone deficiency and MASLD, although evidence for the bidirectional nature of this relationship remains asymmetric but supports a clinically relevant endocrine-hepatic axis. T deficiency appears independently linked to MASLD onset and severity beyond the effects of age and adiposity. These findings underscore the need for reciprocal screening of liver health and gonadal status in at-risk men and highlight the importance of prospective studies and randomized trials to determine whether correcting T deficiency may modify MASLD progression.

Read PDF

Similar papers

Open access Aug 2026

EP575 - ECE_1616 - Metabolic dysfunction–associated steatotic liver disease and testosterone serum levels: converging evidence from real-world observational data and meta-analysis

Real-world data support meta-analytic evidence and suggest that testosterone deficiency contributes to hepatic steatosis and fibrosis mainly through increased adiposity, while TRT may mitigate liver risk by modulating body composition and metabolic dysfunction.

G. Spaggiari, L. Valentina, C. Felicani et al. · 0 citations
Review Open access Aug 2026

Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysis.

Available treatments showed distinct outcome-specific effects, but no single strategy was consistently superior across all outcomes, and these findings should inform individualized treatment decisions rather than a definitive treatment ranking.

Liang-Liang Yang, Xin-Lei He, Shi-Ze Wang et al. · 0 citations
Review Open access Sep 2026

Hypogonadism in aging men: Impact of comorbidities, diagnosis and treatment.

A narrative review addresses unresolved issues in diagnostic criteria, etiological assessment, and the impact of treatment on symptoms and long-term health outcomes in older men.

Serena Anna Ravelli, E. Maseroli, Linda Vignozzi · 0 citations
Review Open access Aug 2026

Testosterone replacement therapy in metabolic dysfunction-associated steatotic liver disease: a bench-to-bedside narrative review

TRT may represent a promising adjunctive therapy for reducing hepatic steatosis and improving the histopathological features of MASH in selected hypogonadal men with MASLD, particularly those with obesity or T2D and significant baseline steatosis; however, routine clinical use will require large, well-powered Phase 3 R...

Yuchang Li, Vassilios Papadopoulos · 0 citations
Open access Aug 2026

EP1363 - ECE_3272 - Central adiposity drives persistent MASLD risk in postmenopausal women with a phenotype of Polycystic Ovary Syndrome

Findings identify central adiposity as a key mechanistic link between PCOS and MASLD and support prioritising waist circumference over BMI for long-term hepatic and metabolic risk stratification in postmenopausal women with a history of PCOS.

E. Armeni, Nektaria Papanikola, A. Augoulea et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.